This article was originally published in The Gray Sheet
Executive SummaryRetains restructuring firm Jay Alix & Associates to develop and implement restructuring plans. Also announced are the resignations of Chairman and CEO Shan Padda and Doron Levitas, vice-chariman and secretary; both will retain their positions as directors of the company. A representative of Jay Alix will be appointed acting CEO. The firm plans to report second quarter earnings "as soon as practicable" after auditors complete a previously announced review, but Sabratek was unable to meet the Aug. 20 deadline for its Form 10-Q. The law firm of Cohen, Milstein, Hausfeld & Toll announced Aug. 25 that they have filed a lawsuit against the company in Chicago federal court on behalf of persons who purchased Sabratek's common stock between May 11 and Aug. 23, 1999
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.